Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
Nikolay N. Murashkin,
Alexander I. Materikin,
Eduard T. Ambarchian,
Roman V. Epishev,
Leonid A. Opryatin,
Roman A. Ivanov,
Daria S. Kukoleva,
Daria G. Kuptsova,
Marina U. Pomazanova https://doi.org/10.15690/vsp.v19i6.2146
Abstract
Psoriasis is chronic inflammatory skin disease that can develop at any age. Approximately 20–30% of all patients report about first rashes before the age of 18. Psoriatic arthritis is one of psoriasis comorbid conditions. Its signs can range from mild to extremely severe destructive forms. Arthralgia, joint stiffness and swelling are the most common symptoms. Early psoriatic arthritis treatment onset allows to control joint damage which usually occurs during the first 2 years of the disease. The moderate and severe course of psoriasis and psoriatic arthritis may require systemic therapy, however, there is not much data on the efficacy and toxicity of systemic agents in the pediatric practice. This article provides the review of studies on etanercept efficacy and safety in children with psoriatic arthritis.
Supporting agencies: The article has been supported by Pfizer
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health;
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences;
Sechenov First Moscow State Medical University (Sechenov University);
Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Galderma, Pierre Fabre, Bayer, Astellas. Libriderm
Alexander I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Alexander I. Materikin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma. Libriderm
Eduard T. Ambarchian
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Eduard T. Ambarchian — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma. Libriderm
Roman V. Epishev
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Roman V. Epishev — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma. Libriderm
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Daria S. Kukoleva
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Daria G. Kuptsova
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Marina U. Pomazanova
National Medical Research Center of Children’s Health;
Clinical Dermatovenerologic Dispensary
Russian Federation
Moscow, Krasnodar
Disclosure of interest:
Russian Federation
Moscow, Krasnodar
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
References
1. Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol Ther. 2009;22(1):34–39. doi: 10.1111/j.1529-8019.2008.01214.x.
2. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987. doi: 10.1016/j.jaad.2009.07.029.
3. Augustin M, Glaeske G, Radtke M, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3): 633–636. doi: 10.1111/j.1365-2133.2009.09593.x.
4. Kruglova LS, Tamrazova OB, Ivanov RA. Psoriasis in childhood: clinical course and management tactics. Journal of International Medicine. ediatrics/Neonatology. 2019; 2(36):19–25. (In Russ).
5. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687. doi: 10.1038/jid.2010.340.
6. Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9): 531–442. doi: 10.1038/nrrheum.2014.106.
7. Mayo Clinic. Psoriatic Arthritis — Symptoms and Causes. 2016. Available online: https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/symptoms-causes/syc-20354076. Accessed on December 12, 2017.
8. Lindqvist URC, Alenius G-M, Husmark T. et al. The Swedish early psoriatic arthritis register — 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol. 2008;35(4):668–673.
9. Gladman DD. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–17. doi: 10.1136/ard.2004.032482.
10. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009;5(11):634–641. doi: 10.1038/nrrheum.2009.210.
11. Nigrovic P. Juvenile psoriatic arthritis: bathwater or baby? J Rheumatol. 2009;36(9):1861–1863. doi: 10.3899/jrheum.090510.
12. Stoll M, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi: 10.1097/BOR.0b013e328348b278.
13. Flato B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: long term outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol. 2009;36(3):642–650. doi: 10.3899/jrheum.080543.
14. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78. doi: 10.1016/0049-0172(73)90035-8.
15. Eder L, Gladman DD. Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep. 2013;15(3):316. doi: 10.1007/s11926-013-0316-4.
16. Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25(12):1409–1414. doi: 10.1111/j.1468-3083.2011.03985.x.
17. Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568. doi: 10.1016/j.rdc.2015.07.001.
18. McGonagle D, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012;225(2):100–109. doi: 10.1159/000341536.
19. Sakkas L, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43(3):325–334. doi: 10.1016/j.semarthrit.2013.04.005.
20. Weiss PF, Chauvin NA, Klink AJ, et al. Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography. Arthritis Rheumatol. 2014;66(1):218–227. doi: 10.1002/art.38197.
21. Coates L, Hodgson R, Conaghan P, Freeston J. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26(6):805–822. doi: 10.1016/j.berh.2012.09.004.
22. Gladman D, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40(8):1357–1359. doi: 10.3899/jrheum.130163.
23. Healy P, Groves C, Chandramohan M, Helliwell P. MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford). 2008; 47(1):92–95. doi: 10.1093/rheumatology/kem315.
24. Tuttle KS, Vargas SO, Callahan MJ, et al. Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatr Rheumatol Online J. 2015;13:7. doi: 10.1186/s12969-015-0003-2.
25. Love T, Gudjonsson J, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis — results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012;39(7): 1441–1444. doi: 10.3899/jrheum.111298.
26. Love T, Gudbjornsson B, Gudjonsson J, Valdimarsson H. Psoria tic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol. 2007;34(10):2082–2088.
27. Aydin S, Castillo-Gallego C, Ash Z, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231–235. doi: 10.1159/000343607.
28. Kruglova LS, Hotko AA, Petriy MA. Early prescription of genetically engineered biological therapy for patients with psoriasis. Medical Alphabet. Dermatology. 2019;1(7):25–28. (In Russ).
29. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis — a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–256. doi: 10.1093/rheumatology/kel214.
30. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi: 10.1016/j.jaad.2005.07.073.
31. Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171:1123–1128. doi: 10.1111/bjd.13272.
32. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasala zine and placebo in the treatment of psoriatic arthritis: a Depart ment Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2013–2020. doi: 10.1002/art.1780391210.
33. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–277. doi: 10.1136/ard.2010.129379.
34. Helliwell P, FitzGerald O, Pedersen R, et al. Comparison of composite disease activity scores in psoriatic arthritis. In: 3th World Psoriasis & Psoriatic Arthritis Conference 2012 “Psoriasis — a global health challenge”, June 27 — July 1, 2012, Stockholm, Sweden. Abstr. pp. 4–5; P009.
35. Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a oneyear multicenter retrospective study. J Dermatolog Treat. 2018; 29(3):217– 219. doi: 10.1080/09546634.2017.1364692.
36. Dogra S, Mahajan R. Biologics in pediatric psoriasis — efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9–16. doi: 10.1080/14740338.2018.1391787.
37. Ramiro S, Smolen JS, Landewe R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016;75(3):490–498. doi: 10.1136/annrheumdis-2015-208466.
38. Coates LC, Kavanaugh A, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014;41(11):2273–2276. doi: 10.3899/jrheum.140875.
39. Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1): i37–i46. doi: 10.1093/rheumatology/kez383.
40. Coates LC, Moverley AR, McParland L, et al. Effect of tight control inflammation in early psoriatic arthritis (TICOPA): a UK multicenter, open-label, randomized controlled trial. Lancet. 2015;386(10012): 2489–2498. doi: 10.1016/S0140-6736(15)00347-5.
41. Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743–750. doi: 10.1038/nrrheum.2016.183.
42. Okazanie meditsinskoj pomoshchi detyam s psoriazom. Baranov AA, Namazova-Baranova LS, Murashkin NN, eds. Moscow: Pediatr; 2016. 64 p. (In Russ).
43. NamazovaBaranova LS, Murashkin NN, Ambarchian ET, Materikin AI. Systemic psoriasis treatment at an early age (part II): issues of biological therapy. Vestnik Dermatologii i Venerologii. 2017;(6):100–107. (In Russ). doi: 10.25208/0042-4609-2017-93-6-100-107.
44. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a Randomized, Controlled Phase 3 Trial. Arthritis Rheumatol. 2019;71(7):1112–1124. doi: 10.1002/art.40851.
45. Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–3. doi: 10.1016/j.jaad.2015.09.056.
46. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70. doi: 10.1016/j.jaad.2010.02.060.
47. Paller A, Pariser D, Siegfried E, Kricorian G. Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study. Conference: 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. J Am Acad Dermatol. 2010;62(3 Suppl 1):AB11.
48. Murashkin NN, Ambarchian ET. Comparative Evaluation of the Treatment Efficacy and Safety of TNF and IL12/23 Inhibitors in Children With Psoriasis. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2018;15(6):455–463. (In Russ). doi: 10.15690/pf.v15i6.1983.
49. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49(2 Supple):105–111. doi: 10.1016/mjd.2003.554.
50. Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent Etanercept Therapy in Pediatric Patients With Psoriasis. J Am Acad Dermatol. 2010;63(5):769–774. doi: 10.1016/j.jaad.2009.10.046.
51. Foeldvari I, Constantin T, Vojinovic J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitisrelated arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Paediatric Rheumatology International Trials Organisation (PRINTO). Arthritis Res Ther. 2019;21(1):125. doi: 10.1186/s13075-019-1916-9.
Review
For citations:
Murashkin N.N., Materikin A.I., Ambarchian E.T., Epishev R.V., Opryatin L.A., Ivanov R.A., Kukoleva D.S., Kuptsova D.G., Pomazanova M.U. Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood. Current Pediatrics. 2020;19(6):444-451. (In Russ.) https://doi.org/10.15690/vsp.v19i6.2146
Views:
1717
Email this article 
